| Primary |
| Decreased Appetite |
23.3% |
| Drug Use For Unknown Indication |
11.0% |
| Appetite Disorder |
8.6% |
| Product Used For Unknown Indication |
8.6% |
| Weight Decreased |
8.2% |
| Chemotherapy |
5.3% |
| Increased Appetite |
3.3% |
| Neoplasm Malignant |
3.3% |
| Cachexia |
2.9% |
| Endometrial Sarcoma |
2.9% |
| Hypertension |
2.9% |
| Arrhythmia |
2.4% |
| Breast Cancer |
2.4% |
| Endometrial Cancer |
2.4% |
| Malnutrition |
2.4% |
| Antiretroviral Therapy |
2.0% |
| Atrial Fibrillation |
2.0% |
| Constipation |
2.0% |
| Pain |
2.0% |
| Prophylaxis |
2.0% |
|
| Deep Vein Thrombosis |
22.9% |
| Pulmonary Embolism |
15.7% |
| Meningioma |
9.2% |
| Death |
6.5% |
| Thrombosis |
6.5% |
| Drug Ineffective |
5.9% |
| Hypogonadism |
4.6% |
| Product Taste Abnormal |
3.9% |
| Oedema |
2.6% |
| Vomiting |
2.6% |
| Adrenal Insufficiency |
2.0% |
| Blood Glucose Increased |
2.0% |
| Dizziness Postural |
2.0% |
| Hypotension |
2.0% |
| Oedema Peripheral |
2.0% |
| Pyrexia |
2.0% |
| Sinus Tachycardia |
2.0% |
| Vaginal Haemorrhage |
2.0% |
| Weight Decreased |
2.0% |
| Weight Increased |
2.0% |
|
| Secondary |
| Breast Cancer |
27.9% |
| Breast Cancer Metastatic |
22.0% |
| Hormone Replacement Therapy |
10.0% |
| Appetite Disorder |
5.6% |
| Drug Use For Unknown Indication |
3.8% |
| Arrhythmia |
3.1% |
| Ill-defined Disorder |
3.1% |
| Product Used For Unknown Indication |
3.1% |
| Non-small Cell Lung Cancer |
2.8% |
| Metastatic Neoplasm |
2.6% |
| Colorectal Cancer |
2.3% |
| Hormone Therapy |
2.3% |
| Decreased Appetite |
1.8% |
| Pain |
1.8% |
| Chemotherapy |
1.5% |
| Prophylaxis |
1.5% |
| Asthenia |
1.3% |
| Blood Pressure Abnormal |
1.3% |
| Prophylaxis Of Nausea And Vomiting |
1.3% |
| Atrial Fibrillation |
1.0% |
|
| Venous Thrombosis |
11.9% |
| Hepatic Failure |
10.4% |
| Weight Decreased |
10.4% |
| Breast Cancer |
7.5% |
| Pulmonary Embolism |
7.5% |
| Hyperhidrosis |
6.0% |
| Cardiac Cirrhosis |
4.5% |
| Deep Vein Thrombosis |
4.5% |
| Hepatic Cirrhosis |
4.5% |
| Somnolence |
4.5% |
| White Blood Cell Count Decreased |
4.5% |
| Breast Cancer Stage Ii |
3.0% |
| Dyspnoea |
3.0% |
| Increased Appetite |
3.0% |
| Malignant Neoplasm Progression |
3.0% |
| Medication Error |
3.0% |
| Tuberculosis |
3.0% |
| Vaginal Haemorrhage |
3.0% |
| Agranulocytosis |
1.5% |
| Ascites |
1.5% |
|
| Concomitant |
| Product Used For Unknown Indication |
20.9% |
| Drug Use For Unknown Indication |
20.2% |
| Prophylaxis |
7.5% |
| Non-small Cell Lung Cancer |
5.1% |
| Pain |
4.3% |
| Decreased Appetite |
4.2% |
| Hypertension |
3.8% |
| Diffuse Large B-cell Lymphoma |
3.5% |
| Multiple Myeloma |
3.4% |
| Nausea |
3.0% |
| Constipation |
2.9% |
| Breast Cancer Metastatic |
2.7% |
| Abdominal Pain |
2.6% |
| Breast Cancer |
2.6% |
| Gastric Ulcer |
2.5% |
| Diarrhoea |
2.4% |
| Anxiety |
2.3% |
| Hepatic Neoplasm Malignant |
2.2% |
| Gastric Cancer |
2.0% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
1.9% |
|
| Death |
13.9% |
| Vomiting |
10.5% |
| Weight Decreased |
10.5% |
| Thrombocytopenia |
7.9% |
| Pneumonia |
7.4% |
| Renal Failure |
4.5% |
| Dyspnoea |
3.8% |
| Pain |
3.8% |
| Renal Failure Acute |
3.6% |
| Respiratory Failure |
3.6% |
| Vision Blurred |
3.6% |
| Diarrhoea |
3.4% |
| Urinary Tract Infection |
3.4% |
| Weight Increased |
3.4% |
| Neutropenia |
3.2% |
| Left Ventricular Dysfunction |
3.1% |
| Pulmonary Embolism |
2.9% |
| Fatigue |
2.5% |
| Wound Treatment |
2.5% |
| Dehydration |
2.3% |
|
| Interacting |
| Decreased Appetite |
100.0% |
|
| International Normalised Ratio Increased |
100.0% |
|
